08:13 AM EDT, 09/17/2024 (MT Newswires) -- Rakovina Therapeutics ( RKVTF ) , which is advancing new cancer therapies based on DNA-damage response technologies, announced Tuesday a research collaboration with Variational AI.

The two parties will work to identify and develop novel small-molecule therapies against DNA-damage response targets for cancer treatment using Variational A's Enki platform.

Rakovina will pay a low upfront fee to initiate work against each selected target and a "TPP Fee" upon exercise of its option to acquire rights to drug candidates meeting a pre-specified target-product profile (TPP). The company will also make additional payments upon achievement of specified development milestones.

Additional financial terms were not disclosed.